​

Dianthus Therapeutics (DNTH) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

DNTH Stock Forecast

Dianthus Therapeutics (DNTH) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $69.00, with a high of $100.00 and a low of $51.00. This represents a 104.93% increase from the last price of $33.67.

$10 $28 $46 $64 $82 $100 High: $100 Avg: $69 Low: $51 Last Closed Price: $33.67

DNTH Stock Rating

Dianthus Therapeutics stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 8 Strong Sell Sell Hold Buy Strong Buy

DNTH Price Target Upside V Benchmarks

TypeNameUpside
StockDianthus Therapeutics104.93%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts134
Avg Price Target$56.00$69.00$64.75
Last Closing Price$33.67$33.67$33.67
Upside/Downside66.32%104.93%92.31%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25211---13
Sep, 25210---12
Aug, 25211---13
Jul, 25210---12
Jun, 25210---12
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 14, 2025Danielle BrillTruist Financial$56.00$34.4262.70%66.32%
Sep 08, 2025Yatin SunejaGuggenheim$100.00$31.73215.16%197.00%
Nov 11, 2024Leland GershellOppenheimer$52.00$28.7381.00%54.44%
Apr 18, 2024Steven SeedhouseRaymond James$51.00$24.15111.18%51.47%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 12, 2025WedbushOutperformOutperformhold
Sep 09, 2025Raymond JamesOutperformOutperformhold
Sep 08, 2025GuggenheimBuyBuyhold
Sep 08, 2025Evercore ISIOutperformOutperformhold
Nov 11, 2024OppenheimerOutperformOutperformhold
Oct 04, 2024GuggenheimBuyBuyhold
Oct 02, 2024OppenheimerOutperforminitialise
Sep 26, 2024H.C. WainwrightUnderperformUnderperformhold
Aug 12, 2024WedbushBuyBuyhold
Jun 27, 2024Cantor FitzgeraldOverweightinitialise

Financial Forecast

EPS Forecast

$-9 $-8 $-7 $-6 $-5 $-4 $-3 $-2 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-8.45$-2.48----
Avg Forecast$-5.53$-2.56$-3.45$-3.94$-4.16$-3.87
High Forecast$-3.77$-2.10$-2.59$-2.80$-2.62$-2.30
Low Forecast$-7.29$-3.00$-4.58$-5.25$-6.71$-6.35
Surprise %52.80%-3.13%----

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.83M$6.24M----
Avg Forecast$2.46M$5.54M$3.71M$4.11M$19.11M$75.36M
High Forecast$2.65M$6.72M$5.54M$6.13M$28.53M$112.53M
Low Forecast$2.12M$4.65M$2.55M$2.82M$13.13M$51.80M
Surprise %14.80%12.46%----

Net Income Forecast

$-85M $-70M $-55M $-40M $-25M $-10M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-43.55M$-84.97M----
Avg Forecast$-28.50M$-13.15M$-18.47M$-20.76M$-24.05M$-19.93M
High Forecast$-19.43M$-10.82M$-13.35M$-14.45M$-13.52M$-11.83M
Low Forecast$-37.57M$-15.48M$-23.59M$-27.08M$-34.57M$-32.70M
Surprise %52.83%546.21%----

DNTH Forecast FAQ

Is Dianthus Therapeutics stock a buy?

Dianthus Therapeutics stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Dianthus Therapeutics is a favorable investment for most analysts.

What is Dianthus Therapeutics's price target?

Dianthus Therapeutics's price target, set by 8 Wall Street analysts, averages $69 over the next 12 months. The price target range spans from $51 at the low end to $100 at the high end, suggesting a potential 104.93% change from the previous closing price of $33.67.

How does Dianthus Therapeutics stock forecast compare to its benchmarks?

Dianthus Therapeutics's stock forecast shows a 104.93% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Dianthus Therapeutics over the past three months?

  • October 2025: 15.38% Strong Buy, 84.62% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 16.67% Strong Buy, 83.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 15.38% Strong Buy, 84.62% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Dianthus Therapeutics’s EPS forecast?

Dianthus Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.45, marking a 39.11% increase from the reported $-2.48 in 2024. Estimates for the following years are $-3.94 in 2026, $-4.16 in 2027, and $-3.87 in 2028.

What is Dianthus Therapeutics’s revenue forecast?

Dianthus Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $3.71M, reflecting a -40.49% decrease from the reported $6.24M in 2024. The forecast for 2026 is $4.11M, followed by $19.11M for 2027, and $75.36M for 2028.

What is Dianthus Therapeutics’s net income forecast?

Dianthus Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-18.473M, representing a -78.26% decrease from the reported $-84.969M in 2024. Projections indicate $-20.762M in 2026, $-24.045M in 2027, and $-19.929M in 2028.